By Sarah Sloat 
 

Bayer AG (BAYN.XE) said Tuesday its investment arm is teaming up with biotechnology startup Khloris Biosciences to develop anti-cancer vaccines to based on stem cells.

Bayer's investment--through its Leaps by Bayer unit--in the project wasn't disclosed.

The cooperation will focus on a kind of stem cells that have potential for anti-cancer vaccines because they share characteristics with cancer cells, such as the ability to self-renew, Bayer said.

"Bayer's development expertise, commercial reach and worldwide network of R&D sites, combined with our scientific knowledge and technology, will increase the chances to bring this potential breakthrough option to patients in need," said Joseph C. Wu, a cofounder of Khloris.

 

Write to Sarah Sloat at sarah.sloat@wsj.com

 

(END) Dow Jones Newswires

April 02, 2019 12:59 ET (16:59 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.